Based on recent scientific findings, we have updated and revised our Panel for Blood and Immune Disorders. Besides including 123 additional genes associated with blood and immune disorders, the most significant change is the separation of the panel into two stand-alone panels: one for genetic blood disorders (BLD) and one for primary immune deficiencies (PID). […]
https://www.cegat.de/web/wp-content/uploads/2018/08/KeyVisual-PID-Color-RGB-WEB.jpg5601920woltershttps://www.cegat.de/web/wp-content/uploads/2017/11/CeGaT_Logo_Neu_horizontal_mit-claim-300x77.pngwolters2018-08-24 10:33:262018-11-09 13:37:15Large Update of the Panel for Blood and Immune Disorders, Separation into New Panels
Based on recent scientific findings, we have updated our Panel for Genetic Skin Diseases (DRM). It is now available in version three. Overall, the panel now comprises 253 genes. The diagnostic sensitivity of existing gene sets has been further increased, and new differential diagnostic options have been made available. Selected gene sets on the panel […]
https://www.cegat.de/web/wp-content/uploads/2018/02/Keyvisual_DRM-WEB.jpg5601920woltershttps://www.cegat.de/web/wp-content/uploads/2017/11/CeGaT_Logo_Neu_horizontal_mit-claim-300x77.pngwolters2018-08-15 16:16:102018-11-09 13:37:22Comprehensive Update of the Panel for Skin Diseases
https://www.cegat.de/web/wp-content/uploads/2018/03/Publikation-Keyvisual-V2-blank-WEB.jpg5791030Sabrina Geberthttps://www.cegat.de/web/wp-content/uploads/2017/11/CeGaT_Logo_Neu_horizontal_mit-claim-300x77.pngSabrina Gebert2018-08-13 11:43:492018-12-11 14:04:26Tdrd6a Regulates the Aggregation of Buc into Functional Subcellular Compartments that Drive Germ Cell Specification.
https://www.cegat.de/web/wp-content/uploads/2018/03/Publikation-Keyvisual-V2-blank-WEB.jpg5791030Sabrina Geberthttps://www.cegat.de/web/wp-content/uploads/2017/11/CeGaT_Logo_Neu_horizontal_mit-claim-300x77.pngSabrina Gebert2018-08-13 10:47:302018-12-11 14:05:57Mutations in the gene PDE6C encoding the catalytic subunit of the cone photoreceptor phosphodiesterase in patients with achromatopsia.
It is essential to precisely identify therapy-relevant genetic changes quickly, cost-efficiently and in compliance with all quality standards. With the knowledge of these tumor-specific mutations, diagnoses can be further expanded to identify individual therapy options and drug combinations. Ineffective therapies and their side effects are avoided and new treatment options become available. “For these clinical […]
https://www.cegat.de/web/wp-content/uploads/2017/07/Tumor-Keyvisual-blank.jpg10801920woltershttps://www.cegat.de/web/wp-content/uploads/2017/11/CeGaT_Logo_Neu_horizontal_mit-claim-300x77.pngwolters2018-08-03 14:45:392018-11-09 13:37:59CeGaT Launches the Molecular Pathology Panel for Targeted Identification of Therapy-Relevant Gene Mutations in Solid Tumors